BioVie to present Phase 2 bezisterim Long COVID trial results at ANA 2026 meeting
Bitget2026/10/14 12:03- BioVie flagged new Phase 2 findings for bezisterim in Long COVID, set for poster presentation at ANA2026 on Oct. 18.
- The company also plans to present initial Phase 2 results for bezisterim in early Parkinson’s disease at the same meeting on Oct. 19.
- Both readouts focus on efficacy and safety observations, with disclosures positioned as new data updates rather than final trial outcomes.
- The presentations are scheduled for Oct. 17–20 in San Diego, giving investors a near-term catalyst across two indications.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
